82 related articles for article (PubMed ID: 1851602)
1. High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.
Buzaid AC; Murren J; Durivage HJ
Am J Clin Oncol; 1991 Jun; 14(3):203-7. PubMed ID: 1851602
[TBL] [Abstract][Full Text] [Related]
2. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
4. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Glover D; Glick JH; Weiler C; Fox K; Guerry D
J Clin Oncol; 1987 Apr; 5(4):574-8. PubMed ID: 3031224
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
7. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
10. Biweekly paclitaxel in the treatment of patients with metastatic breast cancer.
Gelmon KA
Semin Oncol; 1995 Oct; 22(5 Suppl 12):117-22. PubMed ID: 7481853
[TBL] [Abstract][Full Text] [Related]
11. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
12. Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer.
Tolcher AW; Gelmon KA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):28-32. PubMed ID: 7638639
[TBL] [Abstract][Full Text] [Related]
13. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
[TBL] [Abstract][Full Text] [Related]
14. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
[TBL] [Abstract][Full Text] [Related]
15. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.
Demchak PA; Mier JW; Robert NJ; O'Brien K; Gould JA; Atkins MB
J Clin Oncol; 1991 Oct; 9(10):1821-30. PubMed ID: 1655988
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study.
Thigpen JT; Al-Sarraf M; Hewlett JS
Cancer Treat Rep; 1979 Apr; 63(4):525-8. PubMed ID: 445506
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).
Glover D; Ibrahim J; Kirkwood J; Glick J; Karp D; Stewart J; Ewell M; Borden E;
Melanoma Res; 2003 Dec; 13(6):619-26. PubMed ID: 14646626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
